Cyclooxygenase-2 Inhibition Attenuates Abdominal Aortic Aneurysm Progression in Hyperlipidemic Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ghoshal, Sarbani ^a   Loftin, Charles D ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; APOLIPOPROTEIN E; CELECOXIB; CYCLOOXYGENASE 2;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA RUPTURE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; HYPERLIPIDEMIA; INCIDENCE; INFLAMMATION; MALE; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; APOLIPOPROTEINS E; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERLIPIDEMIAS; INCIDENCE; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE;

MUS;

EID: 84870276827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044369     Document Type: Article

References (41)

1. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, et al. (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105: 1641-1649.
2. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM, (1999) Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 29: 884-892.
3. King VL, Trivedi DB, Gitlin JM, Loftin CD, (2006) Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26: 1137-1143.
4. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD, (2007) Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 73: 227-236.
5. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, et al. (2008) Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117: 1302-1309.
6. Davies NM, McLachlan AJ, Day RO, Williams KM, (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225-242.
7. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
8. Gilsbach R, Kouta M, Bonisch H, Bruss M, (2006) Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 40: 173-177.
9. Daugherty A, Manning MW, Cassis LA, (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612.
10. Saraff K, Babamusta F, Cassis LA, Daugherty A, (2003) Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23: 1621-1626.
11. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, et al. (1995) Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96: 318-326.
12. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, et al. (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15: 1145-1151.
13. Drew E, Merkens H, Chelliah S, Doyonnas R, McNagny KM, (2002) CD34 is a specific marker of mature murine mast cells. Exp Hematol 30: 1211-1218.
14. Kujubu DA, Reddy ST, Fletcher BS, Herschman HR, (1993) Expression of the protein product of the prostaglandin synthase- 2/TIS10 gene in mitogen-stimulated swiss 3T3 cells. J Biol Chem 268: 5425-5430.
15. Goergen CJ, Azuma J, Barr KN, Magdefessel L, Kallop DY, et al. (2011) Influences of aortic motion and curvature on vessel expansion in murine experimental aneurysms. Arterioscler Thromb Vasc Biol 31: 270-279.
16. Fatigati V, Murphy RA, (1984) Actin and tropomyosin variants in smooth muscles. Dependence on tissue type. J Biol Chem 259: 14383-14388.
17. Jain M, He Q, Lee WS, Kashiki S, Foster LC, et al. (1996) Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. J Clin Invest 97: 596-603.
18. Papakonstantinou E, Roth M, Block LH, Mirtsou-Fidani V, Argiriadis P, et al. (1998) The differential distribution of hyaluronic acid in the layers of human atheromatic aortas is associated with vascular smooth muscle cell proliferation and migration. Atherosclerosis 138: 79-89.
19. Owens GK, (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75: 487-517.
20. Evanko SP, Johnson PY, Braun KR, Underhill CB, Dudhia J, et al. (2001) Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys 394: 29-38.
21. Chai S, Chai Q, Danielsen CC, Hjorth P, Nyengaard JR, et al. (2005) Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res 96: 583-591.
22. Vorp DA, Vande Geest JP, (2005) Biomechanical determinants of abdominal aortic aneurysm rupture. Arterioscler Thromb Vasc Biol 25: 1558-1566.
23. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT, (2004) Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110: 16-21.
24. Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, et al. (2008) In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ Cardiovasc Imaging 1: 220-226.
25. Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, et al. (2009) Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg 138: 1392-1399.
26. Davis V, Persidskaia R, Baca-Regen L, Itoh Y, Nagase H, et al. (1998) Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 18: 1625-1633.
27. Goodall S, Crowther M, Hemingway DM, Bell PR, Thompson MM, (2001) Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 104: 304-309.
28. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, et al. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110: 625-632.
29. Hultgardh-Nilsson A, Lovdahl C, Blomgren K, Kallin B, Thyberg J, (1997) Expression of phenotype- and proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc Res 34: 418-430.
30. Risinger GM Jr, Updike DL, Bullen EC, Tomasek JJ, Howard EW, (2010) TGF-beta suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BB. Am J Physiol Cell Physiol 298: C191-201.
31. Jung HO, Uhm JS, Seo SM, Kim JH, Youn HJ, et al. (2010) Angiotensin II-induced smooth muscle cell migration is mediated by LDL receptor-related protein 1 via regulation of matrix metalloproteinase 2 expression. Biochem Biophys Res Commun 402: 577-582.
32. Goodall S, Porter KE, Bell PR, Thompson MM, (2002) Enhanced invasive properties exhibited by smooth muscle cells are associated with elevated production of MMP-2 in patients with aortic aneurysms. Eur J Vasc Endovasc Surg 24: 72-80.
33. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, et al. (2006) Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 38: 343-349.
34. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, et al. (2007) Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 39: 1488-1493.
35. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, et al. (2007) MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet 16: 2453-2462.
36. Inamoto S, Kwartler CS, Lafont AL, Liang YY, Fadulu VT, et al. (2010) TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc Res 88: 520-529.
37. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475-481.
38. Hippisley-Cox J, Coupland C, (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366.
39. McGettigan P, Henry D, (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8: e1001098.
40. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117: 2104-2113.
41. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, et al. (2009) Rationale, design, and governance of prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 157: 606-612.